Shockwave Therapy for TMJ & Masseter Myofascial Pain: What Does the Evidence Show?

Shockwave therapy now has a meaningful randomized-trial evidence base in temporomandibular disorders, particularly myogenous presentations involving the chewing muscles. Recent meta-analyses generally find improvements in pain and maximal mouth opening, but protocols and diagnostic populations vary considerably. ESWT has also not consistently outperformed other active conservative treatments when used alone.

The most defensible interpretation is therefore not that shockwave "fixes the TMJ," but that it can be a useful adjunct for appropriately selected painful TMD, especially when the dominant problem is muscular.

Why the diagnosis comes first

Temporomandibular disorders are not one condition. The Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) separate muscle pain (myalgia), joint pain (arthralgia) and headache attributed to TMD from intra-articular disorders such as disc displacement (Schiffman, 2014). A shockwave trial in patients with painful chewing muscles answers a different question from one that mixes muscle, joint and disc problems together. Reading the evidence well means asking which patients were studied, not just whether shockwave "worked."

The largest 2026 meta-analysis

A 2026 meta-analysis of 18 randomized trials involving 1,150 participants found that ESWT reduced pain by approximately 1.3 points and increased maximal mouth opening by approximately 3.8 mm compared with control interventions. Heterogeneity was extremely high, however, which means the studies differed substantially in patient selection, protocols and treatment comparisons.

The trials compared ESWT with rehabilitation interventions, sham therapy, medication or no treatment. The pooled pain difference was −1.28 (95% CI −1.96 to −0.61; I² 95%), and the pooled mouth-opening difference was 3.76 mm (95% CI 1.52 to 5.99; I² 97%). The dysfunction index did not improve significantly (mean difference −0.05; 95% CI −0.13 to 0.03). The authors explored heterogeneity by shock number, treatment period and sex, and concluded that the effect should be interpreted with caution (Chen, 2026).

An I² above 90% means most of the variation between studies reflects real differences in how they were done rather than chance. The pooled number is a useful signal of direction, not a precise estimate of what any one patient will experience.

Alone or as an adjunct?

A second 2026 meta-analysis of 14 randomized trials and 1,107 participants found no statistically significant advantage for ESWT alone over active treatment for pain. The more consistent signal appeared when ESWT was added to another conservative treatment, where both pain and mouth-opening outcomes improved.

Compared with active controls, ESWT alone produced a pain difference of −0.81 points (95% CI −1.77 to 0.16; p = 0.06; I² 0%) and no significant mouth-opening benefit. As an adjunct, ESWT improved pain by 0.94 points (95% CI 0.61 to 1.26; p < 0.0001; I² 19.5%) and mouth opening with a standardized mean difference of 0.69 (95% CI 0.48 to 0.90; p < 0.0001; I² 45.5%). The authors cautioned that overall study quality was generally low and long-term follow-up was limited (Liu, 2026).

The current evidence arguably supports ESWT most strongly as part of a broader conservative program rather than as a stand-alone solution. That is the single most important point for anyone considering shockwave for jaw pain.

A third 2026 meta-analysis

A separate 2026 meta-analysis also found a clinically favorable pain signal and improvement in mouth opening, adding consistency to the overall direction of evidence. It included 13 controlled studies with 678 participants. After sensitivity analysis, seven studies showed greater pain improvement with ESWT (mean difference −1.77; 95% CI −2.10 to −1.44; I² 36%), and eight showed better mouth opening (standardized mean difference 0.50; 95% CI 0.26 to 0.73; I² 31%). The authors noted methodological limitations and a regional concentration of the evidence (Yu, 2026).

These meta-analyses include overlapping primary trials. Three analyses reaching a similar direction is reassuring, but they are largely reanalyzing many of the same studies rather than providing three independent confirmations.

The placebo-controlled myogenous TMD trial

A randomized placebo-controlled trial of 64 patients with myogenous TMD found significantly lower pain in the ESWT group than placebo through the six-week post-treatment assessment after three treatment sessions. The trial is particularly relevant because it studied myogenous TMD rather than treating all TMD diagnoses as one condition, and it excluded patients whose pain involved the joint only.

Thirty-three patients received focused shockwave to the involved masseter and 31 received the same procedure with a placebo stand-off that blocked energy transmission, one session per week for three weeks. Pain was measured a week after each session and at six weeks and three months after the last session. Pain was significantly lower in the ESWT group at each assessment through six weeks, falling from 5.6 to 3.1 on a 0-10 scale at six weeks, compared with 5.9 to 4.3 with placebo. Jaw-function measures did not differ significantly between groups, and no significant complications or adverse effects were reported (Law, 2025). At three months, pain scores were still numerically lower with ESWT (3.0 vs 4.1 on a 0-10 scale), but the difference was no longer statistically significant (p = 0.059), so the benefit should not be described as established beyond the six-week assessment.

Earlier randomized trials

A randomized 80-patient comparison. Patients with myofascial pain and TMD received radial shockwave once a week for four weeks or ultrashort-wave therapy five days a week for four weeks. Both groups improved in pain, and the shockwave group also improved in pain-free mouth opening, mandibular movement, joint noise, joint pressure and the dysfunction index. The authors reported better post-treatment values with shockwave than with ultrashort wave on these measures (Li and Wu, 2020). A randomized 80-patient study therefore found broad improvements after ESWT across pain, pain-free mouth opening and several jaw-function measures. Because ultrashort wave is not a standard comparison today and reporting was limited, the study should not be simplified into a claim that shockwave was universally superior.

A pilot placebo trial with one-year follow-up. Forty-one patients with myogenous TMD were randomized to focused shockwave to the masseter or placebo, and 26 (14 ESWT, 12 placebo) completed one-year follow-up. A smaller pilot trial with one-year follow-up found improvements in both ESWT and placebo groups. ESWT showed numerically greater improvement, but between-group statistical significance was not demonstrated. No major complications occurred (Li, 2022).

A 2025 pilot trial with medication. Sixty patients with myogenic TMD received shockwave plus drug therapy or ultrashort wave plus drug therapy. Both groups improved in pain and mouth opening, and the shockwave group showed greater improvement in pain, mouth opening and friction indexes. The authors cautioned that the small sample and lack of prospective registration limit interpretation (Zhang, 2025). Because both groups received medication, this study supports shockwave as an adjunct rather than as proof of stand-alone efficacy.

Radial, focused or unspecified?

Shockwave studies in TMD did not all use the same technology, and they should not all be labeled radial or focused.

The two placebo-controlled trials used focused shockwave on the masseter, while at least one positive comparative trial used radial shockwave. The evidence does not establish that one modality is better than the other for TMD.

Why there is no universal TMJ shockwave protocol

The evidence supports a treatment effect more clearly than it supports one universal protocol. Studies differ in modality, energy, pulse count, frequency, treatment location, number of sessions, the diagnosis studied and the comparison treatment. The placebo-controlled trial used three weekly sessions of 500 focused pulses on the masseter, while the 80-patient radial trial used 1,000 to 1,500 pulses weekly for four weeks. Meta-analyses pool these different approaches together, which is part of why heterogeneity is so high.

What the wider comparative research shows

A 2026 network meta-analysis comparing several treatments for myofascial TMD also found substantial uncertainty across intervention rankings, reinforcing that no single modality should be treated as universally dominant. Across 14 randomized trials and 674 patients, several interventions showed short-term pain relief compared with basic treatment, but much of the evidence was low or very low certainty, and the authors stated the rankings should generate hypotheses rather than be read as established superiority (Ma, 2026).

Recent comparative research also supports the broader principle that TMD responds to multiple conservative rehabilitation approaches, which is another reason not to position one modality as universally necessary. A 2026 network meta-analysis of manual therapy, exercise, low-level laser, therapeutic ultrasound and TENS found pain improvement across these approaches, with manual therapy ranking highest for mouth opening (Lin, 2026). That analysis did not include shockwave.

Why myogenous TMD is the strongest use case

The placebo-controlled trials treated the masseter in patients with myogenous TMD, the population in which shockwave has the most direct evidence. Shockwave is a mechanical stimulus delivered to superficial soft tissue, and the masseter is a superficial muscle that can be treated over the jaw without aiming energy into the joint, the ear or the skull. For these reasons, the strongest Novo use case is selected masseter and masticatory-muscle pain confirmed on examination, not joint mechanics.

Shockwave is not used to reposition a displaced disc, correct jaw alignment, restore disc-condyle anatomy, reverse joint degeneration or release mechanical locking. When intra-articular pathology dominates, dental or oral and maxillofacial referral may be required.

Where shockwave fits with other care

TMD conservative care may include jaw education, load modification, controlled jaw movement, muscle rehabilitation, manual therapy and cervical treatment when relevant. Shockwave should fit into a diagnosis-specific rehabilitation plan rather than replace movement, load management or manual treatment when those are indicated. Manual treatment may reduce painful muscle restriction and improve comfortable movement in selected myogenous presentations, but it does not mechanically reposition an internal joint disc.

Safety on the face

Treatment is kept superficial, controlled and anatomically plausible: directed at the masseter over the jaw, angled laterally, and away from the eye, the ear canal, the temporal artery, the skull and other neurovascular structures. It is not delivered inside the mouth or aimed indiscriminately over the joint. New numbness, facial swelling, bruising or worsening pain is a reason to stop and reassess.

Who might be a candidate

The best candidates have persistent jaw or facial pain that behaves like masseter or masticatory-muscle pain on examination, after dental, neuropathic and other medical causes have been considered, and whose symptoms have not settled with education, load management and jaw exercise. Painful clicking alone, persistent locking or a primarily intra-articular problem is a reason for dental or orofacial assessment rather than shockwave.

The bottom line

ESWT has direct randomized and meta-analytic support for selected painful TMD, with the strongest clinical fit in myogenous and masticatory-muscle pain. The evidence is promising and directly relevant, but not definitive: diagnoses, protocols and comparisons vary, study quality is often low, long-term data are limited and the meta-analyses overlap. Shockwave is best used as part of a broader conservative program.

How Novo uses this evidence

We first determine whether jaw pain is muscular, joint-related, cervical, dental or neurologic. When masseter or masticatory-muscle pain is confirmed, shockwave may be added to jaw movement, load management and manual treatment. See how we approach TMJ, jaw and masseter pain, how to distinguish TMJ joint pain from masseter muscle pain, and how temporalis pain relates to headache.

References

• Chen L, Luo Y, Zhang L, Zhang X, Chen Y, Hu D. Extracorporeal shock wave therapy for temporomandibular disorders: efficacy on pain, maximal mouth opening, and dysfunction: a meta-analysis of randomized controlled trials. Frontiers in Rehabilitation Sciences. 2026;7:1883205. PMID 42494855. (link)
• Liu S, Shuai Y, Ye L, Tan S, Wang Y, Wu D. Effectiveness of extracorporeal shock wave therapy for temporomandibular disorders: a systematic review and meta-analysis. Journal of Oral & Facial Pain and Headache. 2026;40(3):65-75. PMID 42220288. (link)
• Yu H, Chen G, Enayirilla P, Zhang X, Ren Y, Chi X, et al. The efficacy of extracorporeal shock wave therapy for temporomandibular joint disorders: a meta-analysis. Journal of Oral Rehabilitation. 2026;53(10):1823-1835. PMID 42286850. (link)
• Law KW, Yeung AWK, Leung YY. Safety and efficacy of shockwave therapy for myogenous temporomandibular disorders: early post-treatment results. International Dental Journal. 2025;75(6):103923. PMID 40992027. (link)
• Li W, Wu J. Treatment of temporomandibular joint disorders by ultrashort wave and extracorporeal shock wave: a comparative study. Medical Science Monitor. 2020;26:e923461. PMID 32564051. (link)
• Li DTS, Li KY, Leung YY. Myogenous temporomandibular disorders: diagnostic concepts and prospective pilot study on extracorporeal shockwave therapy. Diagnostics. 2022;13(1):51. PMID 36611343. (link)
• Zhang S, Jiang Y, Gao D, Zhou Z, Zhang Q. Pilot randomized controlled trial of extracorporeal shock wave therapy for temporomandibular joint disorders. Journal of Back and Musculoskeletal Rehabilitation. 2025;38(3):624-632. PMID 39973094. (link)
• Ma F, Jia B, Liu Z, Pei X, Liu X, Li H, et al. Comparison and ranking of interventions for temporomandibular disorders-myofascial pain syndrome: a Bayesian network meta-analysis based on randomized controlled trials. BMC Oral Health. 2026;26(1). PMID 42010612. (link)
• Lin LH, Hsieh GJ, Lin TY, Chang KV, Wu WT, Özçakar L. Effectiveness of manual therapy, exercise, low-level laser therapy, ultrasound, and transcutaneous electrical nerve stimulation in reducing pain and improving mouth opening in temporomandibular joint disorders: a network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2026;105(25):e49263. PMID 42332459. (link)
• Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for clinical and research applications. Journal of Oral & Facial Pain and Headache. 2014;28(1):6-27. PMID 24482784. (link)